What is AIGEN Sciences?
Founded in 2021 and headquartered in Seoul, South Korea, AIGEN Sciences Inc. is at the forefront of AI-driven drug discovery. The company has developed a sophisticated platform designed to identify high-potency drugs. Its technology aims to achieve desired cellular-level activity while minimizing off-target effects and toxicity, a critical advancement in pharmaceutical research and development. This focus positions AIGEN Sciences as a key player in the competitive biotech landscape, leveraging artificial intelligence to accelerate the creation of safer and more effective therapeutics.
How much funding has AIGEN Sciences raised?
AIGEN Sciences has raised a total of $8.8M across 1 funding round:
Series A
$8.8M
Series A (2024): $8.8M with participation from Quad Investment Management, Premier Partners, and Partners Investment
Key Investors in AIGEN Sciences
Quad Investment Management
Quad Investment Management is an established investment manager overseeing significant equity assets, with a focus on providing differentiated portfolio management services. Their involvement suggests a strategic alignment with AIGEN Sciences' long-term growth objectives.
Premier Partners
Premier Partners offers a comprehensive suite of services including tax, payroll, and financial management, indicating a potential interest in the operational and financial structuring aspects of AIGEN Sciences' expansion.
Partners Investment
Partners Investment Co., Ltd. is a South Korean private equity and venture capital firm specializing in buyouts and start-ups, particularly within the information technology and biotechnology sectors. Their investment highlights a strong belief in AIGEN Sciences' technological innovation and market potential.
What's next for AIGEN Sciences?
The substantial Series A financing, characterized as a major strategic investment, signals AIGEN Sciences' readiness for significant scaling and market penetration. This capital infusion is expected to fuel the expansion of its research and development capabilities, potentially accelerating the clinical trial pipeline for its identified drug candidates. The company's focus on precision and safety in drug discovery, powered by AI, positions it for substantial growth and potential partnerships within the global pharmaceutical industry. Future endeavors will likely involve further validation of its platform and the progression of its lead compounds through regulatory pathways.
See full AIGEN Sciences company page
